Sanjay Subramanian was named Chief Financial Officer of Scynexis Inc, succeeding Ivor Macleod. As of November 6, 2026, Scynexis Inc has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 20, 2026 to September 22, 2026, naming 3 appointments and 2 departures (Form 8-K, September 10, 2026).
SCYNEXIS INC named a new Director on Sep 22. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Scynexis Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Steven K. Burke · Role: Director · Effective: 2026-09-18 · 8-K, 2026-09-22
- · In / out: Out · Person: Ivor Macleod · Role: Chief Financial Officer · 8-K, 2026-09-10
- · In / out: Out · Person: Steven C. Gilman · Role: Director · 8-K, 2026-04-20
Scynexis Inc reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-20 to 2026-09-22. They name 4 people, with 3 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Scynexis Inc files it.
Also on the record for Scynexis Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 5.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Great Point Partners, LLC | 9.99% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G, by Adage Capital Management, L.P. | 9.99% of the class | 5%+ stakes | Source |
| July 20, 2026 | Stake report, Schedule 13G/A, by Federated Hermes, Inc. | 4.03% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by Federated Hermes, Inc. | 4.45% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 6.2% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13G, by CVI Investments, Inc. | 6.7% of the class | 5%+ stakes | Source |
| April 8, 2026 | Stake report, Schedule 13G, by Squadron Master Fund LP | 9.6% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13G, by Great Point Partners, LLC | 9.99% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Avidity Partners Management LP | 9.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by KINGDON CAPITAL MANAGEMENT, L.L.C. | — | 5%+ stakes | Source |
| January 8, 2026 | Stake report, Schedule 13G/A, by Federated Hermes, Inc. | 8.42% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Scynexis Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Scynexis Inc and the records around it.
Scynexis Inc elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Kingdon Capital Management, L.L.C. also filed stake reports on 2 other companies: enVVeno Medical Corporation (May 2026), Jasper Therapeutics, Inc. (Nov 2025)
- Avidity Partners Management LP also filed stake reports on 5 other companies: Context Therapeutics Inc. (May 2026), Immunic, Inc. (Apr 2026), Perspective Therapeutics, Inc. (Mar 2026)
- Federated Hermes, Inc. also filed stake reports on 13 other companies: EyePoint (Nov 2026), Arcturus Therapeutics Holdings Inc. (Oct 2026), Forte Biosciences, Inc. (Sep 2026)
Watch Scynexis Inc
Get an email when Scynexis Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Scynexis Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Scynexis Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Scynexis Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-22 | In | Director | 2026-09-18 | 8-K, 2026-09-22 | |
| 2026-09-22 | In | 8-K, 2026-09-22 | |||
| 2026-09-10 | Out | Chief Financial Officer | 8-K, 2026-09-10 | ||
| 2026-09-10 | In | Chief Financial Officer | 8-K, 2026-09-10 | ||
| 2026-04-20 | Out | Director | 8-K, 2026-04-20 |
Who leads Scynexis Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Steven K. Burke, appointed, effective 2026-09-18 (filed 2026-09-22).
- Chief Financial Officer: Ivor Macleod, departure reported (filed 2026-09-10). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Scynexis Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Scynexis Inc, with the record behind each one.
Find candidates like Director at Scynexis IncEvery change, in the filing's words
Appointed: Steven K. Burke, Director, effective 2026-09-18
On September 18, 2026, the Board of Directors (the "Board") of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") appointed Steven K. Burke, M.D., as a member of the Board, effective September 18, 2026.
Appointed: Steven K. Burke
In addition, the Board appointed Dr. Burke as a member of the Nominating and Corporate Governance Committee of the Board.
- Dr. Burke will serve until SCYNEXIS's 2027 Annual Meeting of Stockholders and until his successor is duly elected and qualified.
- As a non-employee director, Dr. Burke may elect to receive nonstatutory stock options in lieu of all or a portion of the cash compensation to which he would otherwise be entitled, as described above.
Departing: Ivor Macleod, Chief Financial Officer
On September 9, 2026, the then-current Chief Financial Officer of SCYNEXIS, Inc. (the "Company" or "SCYNEXIS"), Ivor Macleod, CPA, MBA, notified the Company of his intent to retire.
Appointed: Sanjay Subramanian, Chief Financial Officer
On September 10, 2026, the Company announced that Sanjay Subramanian, MBA, has been appointed to serve as SCYNEXIS's Chief Financial Officer, in which role he will be SCYNEXIS's principal financial officer and principal accounting officer.
- Mr. Macleod ceased serving as the Company's Chief Financial Officer, principal financial officer and principal accounting officer effective September 9, 2026.
- Mr. Macleod will remain with the Company through October 9, 2026 to support a smooth transition, after which his employment with the Company will end.
- Mr. Subramanian's first date of employment was September 9, 2026.
- SCYNEXIS and Mr. Subramanian are parties to an employment agreement, effective as of September 9, 2026, setting forth the terms of his employment as SCYNEXIS's Chief Financial Officer.
- Pursuant to the terms of the employment agreement, Mr. Subramanian will receive an annual base salary of $500,000, a one-time sign-on bonus of $20,000, a discretionary annual performance bonus of up to 40% of his base salary, and a stock option to purchase 100,000 shares of SCYNEXIS common stock at an exercise price equal to the closing price of SCYNEXIS common stock on the date of grant, vesting over four years.
Departing: Steven C. Gilman, Director
On April 16, 2026, Steven C. Gilman, a member of the Board of Directors (the "Board") of SCYNEXIS, Inc. (the "Company"), notified the Company of his intent to retire as a member of the Board and therefore not stand for reelection at the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").
- Accordingly, Dr. Gilman's term as a director will end when his current term expires at the 2026 Annual Meeting.
- Dr. Gilman will remain in his roles as the Chair of the Compensation Committee and a member of the Nominating and Corporate Governance Committee of the Board until the conclusion of the 2026 Annual Meeting.
- The Company's management and the Board thank Dr. Gilman for his years of service and valuable contributions to the Company.
- Dr. Gilman's resignation was not the result of any disagreement with the Company on any matter related to the Company's operations, policies, practices or strategy, the Company's management or the Board.
Tools for this story
Each opens in a new tab, filled in for Scynexis Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.